Paysign, Inc. to Present at the Planet MicroCap Las Vegas 2026

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. to Present at the Planet MicroCap Las Vegas 2026.

Business Wire • Jun 2, 2026

Paysign, Inc. to Present at the Barrington Research Virtual Spring Investment Conference

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. to Present at the Barrington Research Virtual Spring Investment Conference.

Business Wire • May 27, 2026

Why Paysign Plunged Today

Paysign delivered over 50% growth in the first quarter, surging past estimates. However, management guided conservatively, despite the strong quarter.

The Motley Fool • May 13, 2026

Paysign, Inc. (PAYS) Q1 2026 Earnings Call Transcript

Paysign, Inc. (PAYS) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 13, 2026

Paysign Q1 Earnings Call Highlights

Paysign NASDAQ: PAYS reported what executives described as the strongest start to a year in the company's history, with first-quarter 2026 revenue rising 50.8% year over year to $28 million and profitability expanding sharply as its patient affordability business became its largest revenue contributor.

MarketBeat • May 13, 2026

Paysign's Patient Affordability Drives 51% Revenue Growth and Significant Margin Expansion for First Quarter 2026

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign's Patient Affordability Drives 51% Revenue Growth and Significant Margin Expansion for First Quarter 2026.

Business Wire • May 12, 2026

Paysign to Host First Quarter 2026 Earnings Call

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign to Host First Quarter 2026 Earnings Call.

Business Wire • Apr 15, 2026

Paysign: The Market Is Finally Repricing A Pharma Margin Story

Paysign is evolving beyond a niche prepaid card processor, with patient affordability now driving higher-margin growth. 2025 results highlight a 40.5% revenue increase to $82M, with pharma revenue surging to $33.9M and gross margin expanding to 59.4%. PAYS trades above peer sales multiples, reflecting its shift to a high-value workflow business, while price-to-cash flow remains attractive if cash conversion holds.

Seeking Alpha • Apr 9, 2026

Paysign Is On A Roll

Paysign remains a buy, supported by strong performance in both Plasma Centers and hypergrowth in Patient Affordability. PAYS's Plasma Center segment holds a 50% market share, adding 115 new centers in FY25, despite revenue per center declining due to plasma surplus. That surplus can disappear, and the Plasma segment can benefit from the BECS, generating high-margin SaaS subscription revenue.

Seeking Alpha • Mar 31, 2026

Why Paysign Stock Is Skyrocketing Today

Paysign posted Q4 earnings that were in line with Wall Street's target and sales that beat expectations. The company's forward guidance is spurring huge gains for the stock.

The Motley Fool • Mar 25, 2026